![Christian de la Tour](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Christian de la Tour
Keine laufenden Positionen mehr
Profil
Christian de la Tour served as Chairman at Ipsen Ltd.
and Ipsen Biopharm Ltd.
He also served as Director at Rhythm Pharmaceuticals, Inc., Funxional Therapeutics Ltd., and Allergan GI Corp.
Mr. de la Tour obtained an undergraduate degree from Institut Supérieur de Gestion.
Ehemalige bekannte Positionen von Christian de la Tour
Unternehmen | Position | Ende |
---|---|---|
Ipsen Biopharm Ltd.
![]() Ipsen Biopharm Ltd. Pharmaceuticals: MajorHealth Technology Part of Ipsen SA, Ipsen Biopharm Ltd. is a British biopharmaceutical company that aims to prolong patients' lives, improve health outcomes, and create a positive impact for patients and society. Founded in 1982, the company is based in Wrexham, UK. Ipsen specializes in the fields of oncology, neuroscience, and rare disease, and creates and manufactures pharmaceutical products to improve patients' lives through research and innovation. | Vorsitzender | - |
RHYTHM PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | - |
Ipsen Ltd.
![]() Ipsen Ltd. Pharmaceuticals: MajorHealth Technology Ipsen Ltd. develops and markets medicinal products. The firm provides Decapepty, Disport, Hexvix, Increlex and Somatuline. The company is headquartered in Slough, the United Kingdom. | Vorsitzender | - |
Funxional Therapeutics Ltd.
![]() Funxional Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Funxional Therapeutics Ltd. is a clinical stage pharmaceutical company, which offers drug and therapeutic development programs. It specializes on anti-inflammatory therapies and compounds. The company was founded by David J. Grainger on August 8, 2011 and is headquartered in Cambridge, the United Kingdom. | Direktor/Vorstandsmitglied | - |
Allergan GI Corp.
![]() Allergan GI Corp. BiotechnologyHealth Technology Allergan GI Corp. develops peptide therapeutics for the treatment of gastrointestinal disorders. It provides RM-493 a small-peptide melanocortin-4 receptor agonist, for the treatment of obesity and diabetes, and RM-131 a small-peptide ghrelin agonist, for the treatment of diabetic gastro paresis and other gastrointestinal functional disorders. The company was founded by Bart Henderson and Elizabeth Stoner in 2008 and is headquartered in Madison, NJ. | Direktor/Vorstandsmitglied | - |
Ausbildung von Christian de la Tour
Institut Supérieur de Gestion | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
RHYTHM PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Ipsen Ltd.
![]() Ipsen Ltd. Pharmaceuticals: MajorHealth Technology Ipsen Ltd. develops and markets medicinal products. The firm provides Decapepty, Disport, Hexvix, Increlex and Somatuline. The company is headquartered in Slough, the United Kingdom. | Health Technology |
Funxional Therapeutics Ltd.
![]() Funxional Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Funxional Therapeutics Ltd. is a clinical stage pharmaceutical company, which offers drug and therapeutic development programs. It specializes on anti-inflammatory therapies and compounds. The company was founded by David J. Grainger on August 8, 2011 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Ipsen Biopharm Ltd.
![]() Ipsen Biopharm Ltd. Pharmaceuticals: MajorHealth Technology Part of Ipsen SA, Ipsen Biopharm Ltd. is a British biopharmaceutical company that aims to prolong patients' lives, improve health outcomes, and create a positive impact for patients and society. Founded in 1982, the company is based in Wrexham, UK. Ipsen specializes in the fields of oncology, neuroscience, and rare disease, and creates and manufactures pharmaceutical products to improve patients' lives through research and innovation. | Health Technology |
Allergan GI Corp.
![]() Allergan GI Corp. BiotechnologyHealth Technology Allergan GI Corp. develops peptide therapeutics for the treatment of gastrointestinal disorders. It provides RM-493 a small-peptide melanocortin-4 receptor agonist, for the treatment of obesity and diabetes, and RM-131 a small-peptide ghrelin agonist, for the treatment of diabetic gastro paresis and other gastrointestinal functional disorders. The company was founded by Bart Henderson and Elizabeth Stoner in 2008 and is headquartered in Madison, NJ. | Health Technology |